Gargiulo, L., Ibba, L., Bianco, M., Giulio, S. D., Alfano, A., Ingurgio, R. C., . . . Narcisi, A. Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: A 52-week single-center real-world study. Taylor & Francis Group.
Chicago Style (17th ed.) CitationGargiulo, Luigi, et al. Upadacitinib 30 mg for the Optimal Management of Moderate-to-severe Atopic Dermatitis: A 52-week Single-center Real-world Study. Taylor & Francis Group.
MLA (9th ed.) CitationGargiulo, Luigi, et al. Upadacitinib 30 mg for the Optimal Management of Moderate-to-severe Atopic Dermatitis: A 52-week Single-center Real-world Study. Taylor & Francis Group.
Warning: These citations may not always be 100% accurate.